Saturday 17 October 2026
Export BIO’s income statement to Excel — free account
Bio-Rad Laboratories, Inc.
BIO Healthcare Medical Devices
Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024. In the quarter to June 2026, revenue was flat, EPS grew 19.0%, free cash flow fell 6.06% and total debt was flat, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.
353.70
11.12
−3.05%
Follow BIO
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 10.84 | 45.62 | 35.25 |
P/S ratio |
2.95 | 3.20 | 2.90 | 3.03 | |
P/FCF ratio |
22.27 | 21.93 | 20.91 | 22.11 | |
P/Operating CF |
62.44 | 50.09 | 69.51 | 79.56 | |
P/B ratio |
1.12 | 1.11 | 1.10 | 1.09 | |
Price to Tangible BV |
1.31 | 1.23 | 1.23 | 1.22 | |
EV/Sales |
2.87 | 3.07 | 2.76 | 2.87 | |
EV/EBITDA |
32.66 | 167.85 | 124.19 | 140.08 | |
EV/Operating CF |
14.92 | 14.89 | 14.02 | 15.10 | |
EV/FCF |
21.64 | 21.03 | 19.90 | 20.95 | |
Quick Ratio |
3.61 | 3.87 | 2.17 | 2.14 | |
Current Ratio |
5.44 | 5.62 | 3.21 | 3.14 | |
Net Debt/EBITDA |
(3.31) | 2.84 | (10.60) | (5.71) | |
Debt/Assets |
12.40% | 11.37% | 12.29% | 11.74% | |
Debt/Equity |
0.18 | 0.16 | 0.18 | 0.17 | |
Asset Turnover |
0.25 | 0.26 | 0.27 | 0.25 | |
Operating CF/Net income |
(0.35) | 0.23 | (0.21) | 0.27 | |
Capex/Depreciation |
0.00 | (0.28) | 0.00 | 0.00 | |
Interest Coverage |
5.31 | (9.83) | 2.77 | 6.00 | |
Research and Development Expense of Revenue |
10.92% | 0.00% | 0.00% | 9.40% | |
Selling, General and Administrative Expense of Revenue |
31.67% | 31.88% | 35.87% | 32.57% | |
Intangible Assets out of Total Assets |
0.10 | 0.07 | 0.08 | 0.07 | |
Share Based Compensation of Revenue |
0.00% | 8.37% | 0.00% | 0.00% | |
Graham Net Nets |
(0.02) | (0.03) | 0.00 | (0.01) | |
Graham Number |
0.00 | 414.65 | 186.92 | 224.21 | |
Earnings Yield |
(8.67%) | 9.22% | 2.19% | 2.84% | |
Free Cash Flow Yield |
4.49% | 4.56% | 4.78% | 4.52% | |
Revenue per Share |
24.25 | 25.43 | 21.96 | 24.34 | |
Operating CF per Share |
4.49 | 6.05 | 4.01 | 3.69 | |
Capex per Share |
(1.18) | (1.68) | (1.11) | (1.20) | |
Free Cash Flow per Share |
3.31 | 4.37 | 2.90 | 2.49 | |
Cash per Share |
52.69 | 56.51 | 58.04 | 60.51 | |
Shareholders Equity per Share |
250.22 | 273.40 | 254.15 | 268.22 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
250.22 | 273.40 | 254.15 | 268.22 | |
Free Cash Flow |
89.20 | 119.10 | 78.20 | 66.60 | |
Working Capital |
2,319.70 | 2,389.20 | 2,025.10 | 2,059.20 | |
Capital Expenditures |
(31.70) | (45.80) | (29.90) | (32.10) | |
Net Current Asset Value |
(117.60) | (216.70) | 3.40 | (57.60) | |
EV/EBIT |
32.66 | 167.85 | 124.19 | 140.08 | |
Capex to Sales |
0.05 | 0.07 | 0.05 | 0.05 | |
Price to Operating Income |
33.63 | 175.01 | 130.46 | 147.89 | |
| Other line items | |||||
Average Receivables |
463.32 | 456.55 | 425.45 | 455.85 | |
Average Payables |
125.49 | 125.65 | 135.50 | 141.40 | |
Average Inventory |
793.74 | 750.35 | 780.30 | 789.70 | |
Average Assets |
10,149.94 | 9,970.30 | 9,658.45 | 10,233.05 | |
Average Common Equity |
7,112.33 | 7,011.45 | 6,765.35 | 7,151.30 |
Columns are period end dates